FI4025188T3 - Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia - Google Patents

Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia Download PDF

Info

Publication number
FI4025188T3
FI4025188T3 FIEP21724652.9T FI21724652T FI4025188T3 FI 4025188 T3 FI4025188 T3 FI 4025188T3 FI 21724652 T FI21724652 T FI 21724652T FI 4025188 T3 FI4025188 T3 FI 4025188T3
Authority
FI
Finland
Prior art keywords
suspension
paliperidone palmitate
dose
paliperidone
palmitate
Prior art date
Application number
FIEP21724652.9T
Other languages
English (en)
Finnish (fi)
Inventor
Srihari Gopal
Raja Venkatasubramanian
Huybrecht T'jollyn
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4025188(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of FI4025188T3 publication Critical patent/FI4025188T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP21724652.9T 2020-11-30 2021-05-07 Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia FI4025188T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (1)

Publication Number Publication Date
FI4025188T3 true FI4025188T3 (fi) 2024-02-21

Family

ID=75888043

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21724652.9T FI4025188T3 (fi) 2020-11-30 2021-05-07 Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia

Country Status (22)

Country Link
US (3) US11304951B1 (cg-RX-API-DMAC7.html)
EP (2) EP4025188B1 (cg-RX-API-DMAC7.html)
JP (2) JP7792959B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250053980A (cg-RX-API-DMAC7.html)
CN (1) CN116583270A (cg-RX-API-DMAC7.html)
AU (3) AU2021386450B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203566A1 (cg-RX-API-DMAC7.html)
DK (1) DK4025188T3 (cg-RX-API-DMAC7.html)
ES (1) ES2973583T3 (cg-RX-API-DMAC7.html)
FI (1) FI4025188T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240074T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065573T2 (cg-RX-API-DMAC7.html)
IL (1) IL303253A (cg-RX-API-DMAC7.html)
LT (1) LT4025188T (cg-RX-API-DMAC7.html)
MX (2) MX2023006366A (cg-RX-API-DMAC7.html)
PL (1) PL4025188T3 (cg-RX-API-DMAC7.html)
PT (1) PT4025188T (cg-RX-API-DMAC7.html)
RS (1) RS65178B1 (cg-RX-API-DMAC7.html)
SI (1) SI4025188T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400077T1 (cg-RX-API-DMAC7.html)
TW (2) TWI877363B (cg-RX-API-DMAC7.html)
WO (1) WO2022111859A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
DK3744326T3 (da) * 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
CN114783258A (zh) 2015-06-19 2022-07-22 詹森药业有限公司 用于药物施用和混合的系统及用于所述系统的适当技术的训练
US20190183896A1 (en) * 2017-12-14 2019-06-20 SpecGx LLC One step milling process for preparing micronized paliperidone esters
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations

Also Published As

Publication number Publication date
KR20250053980A (ko) 2025-04-22
KR20230116013A (ko) 2023-08-03
PT4025188T (pt) 2024-02-29
AU2021386450A9 (en) 2025-03-13
EP4025188B1 (en) 2024-01-10
IL303253A (en) 2023-07-01
DK4025188T3 (da) 2024-03-04
JP7792959B2 (ja) 2025-12-26
ES2973583T3 (es) 2024-06-20
CA3203566A1 (en) 2022-06-02
JP2026027255A (ja) 2026-02-18
AU2026203613A1 (en) 2026-05-28
HRP20240074T1 (hr) 2024-03-29
AU2024204213A1 (en) 2024-07-11
US20260060986A1 (en) 2026-03-05
US20220249495A1 (en) 2022-08-11
KR102794804B1 (ko) 2025-04-10
CN116583270A (zh) 2023-08-11
HUE065573T2 (hu) 2024-06-28
AU2021386450A1 (en) 2023-07-13
PL4025188T3 (pl) 2024-06-17
EP4356966A3 (en) 2024-07-17
TW202222319A (zh) 2022-06-16
RS65178B1 (sr) 2024-03-29
EP4356966A2 (en) 2024-04-24
TW202539685A (zh) 2025-10-16
SI4025188T1 (sl) 2024-03-29
TWI926646B (zh) 2026-05-21
US11304951B1 (en) 2022-04-19
AU2024204213B2 (en) 2026-02-26
AU2021386450B2 (en) 2024-03-21
SMT202400077T1 (it) 2024-03-13
TWI877363B (zh) 2025-03-21
JP2023552329A (ja) 2023-12-15
MX2023006366A (es) 2023-08-07
LT4025188T (lt) 2024-03-12
WO2022111859A1 (en) 2022-06-02
MX2024009188A (es) 2024-08-06
EP4025188A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
FI4025187T3 (fi) Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
FI4025189T3 (fi) Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
HRP20240074T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
JP2023552329A5 (cg-RX-API-DMAC7.html)
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
JP2023552149A5 (cg-RX-API-DMAC7.html)
ME02549B (me) Cns dostava terapeutskih agensa
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
RU2361593C3 (ru) Комбинация азеластина и стероидов
WO2011160136A3 (en) Progesterone containing oral dosage forms and related methods
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
JP3597333B2 (ja) 急性鼻炎を処置するための医薬製剤
IL291556B2 (en) Methods and compositions for administration of arylsulfatase A to the central nervous system
JP2023551009A5 (cg-RX-API-DMAC7.html)
JP2012520882A5 (cg-RX-API-DMAC7.html)
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
US20140171389A1 (en) Methods for treating cancer
HUP0202243A2 (hu) Ketotiféntartalmú szemészeti készítmény
US20060241037A1 (en) Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
CA2399505A1 (en) Nasal calcitonin formulations
JP2002537255A (ja) リウマチ性炎症性プロセスに対する5−ht3レセプターアンタゴニストの全身的使用
MX2021008208A (es) Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
ES2197781B1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.